Wealthspire Advisors (New York)’s Bionano Genomics BNGO Stock Holding History

Wealthspire Advisors (New York)’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$4	–	1271
2025 Q3	$4	Buy	+2	New	+$6	﹤0.01%	3053
2022 Q3	–	Sell	-19	Closed	-$16K	–	515
2022 Q2	$16K	Buy	+19	New	+$19.5K	﹤0.01%	495
2021 Q2	–	Sell	-31	Closed	-$151K	–	406
2021 Q1	$151K	Buy	+31	New	+$175K	﹤0.01%	686

Other funds holding BNGO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

Wealthspire Advisors (New York)'s BNGO Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Bionano Genomics (BNGO) in Q4 2025, closing a stake of 2 shares — an estimated $4 sold.

Wealthspire Advisors (New York) first reported a position in BNGO in Q1 2021 and held it in 3 quarters. The position peaked at $151K in Q1 2021. 32 funds tracked by Wall St. Rank hold BNGO as of Q4 2025.

Wealthspire Advisors (New York) reported no remaining Bionano Genomics position as of Q4 2025 after selling out during the quarter.
Wealthspire Advisors (New York) sold 2 Bionano Genomics shares in Q4 2025, an estimated $4.
Wealthspire Advisors (New York) first reported a position in Bionano Genomics in Q1 2021 and held it in 3 quarters.
Wealthspire Advisors (New York)'s Bionano Genomics position peaked at $151K in Q1 2021.
32 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.